Evolus, Inc. EOLS

EOLS Company Overview

Evolus, Inc. is a performance beauty company operating in the medical aesthetics industry, focused on developing, commercializing, and marketing products for aesthetic and therapeutic use. The company’s core offering is Jeuveau®, a proprietary botulinum toxin type A injectable used for the temporary improvement in the appearance of moderate to severe glabellar lines. Evolus primarily generates revenue through product sales to aesthetic physicians, dermatologists, plastic surgeons, and medical spas.

Founded in 2012, Evolus was established to build a differentiated, customer-centric aesthetics company with a singular focus on neurotoxins. The company completed its initial public offering in 2018 and has since expanded its commercial footprint beyond the United States. Evolus positions itself as a focused challenger brand, emphasizing physician engagement, transparent pricing, and a streamlined product portfolio rather than a broad multi-product platform.